Logo image of MTCR

METACRINE INC (MTCR) Stock Fundamental Analysis

NASDAQ:MTCR - Nasdaq - US59101E1038 - Common Stock - Currency: USD

0.4949  0 (-0.02%)

After market: 0.4701 -0.02 (-5.01%)

Fundamental Rating

1

MTCR gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. MTCR may be in some trouble as it scores bad on both profitability and health. MTCR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MTCR has reported negative net income.
In the past year MTCR has reported a negative cash flow from operations.
MTCR Yearly Net Income VS EBIT VS OCF VS FCFMTCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

The profitability ratios for MTCR are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTCR Yearly ROA, ROE, ROICMTCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MTCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTCR Yearly Profit, Operating, Gross MarginsMTCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, MTCR has more shares outstanding
Compared to 1 year ago, MTCR has a worse debt to assets ratio.
MTCR Yearly Shares OutstandingMTCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
MTCR Yearly Total Debt VS Total AssetsMTCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.64, we must say that MTCR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MTCR (-5.64) is worse than 72.53% of its industry peers.
A Debt/Equity ratio of 0.34 indicates that MTCR is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.34, MTCR is not doing good in the industry: 75.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -5.64
ROIC/WACCN/A
WACCN/A
MTCR Yearly LT Debt VS Equity VS FCFMTCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 12.15 indicates that MTCR has no problem at all paying its short term obligations.
With a decent Current ratio value of 12.15, MTCR is doing good in the industry, outperforming 78.02% of the companies in the same industry.
MTCR has a Quick Ratio of 12.15. This indicates that MTCR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MTCR (12.15) is better than 78.02% of its industry peers.
Industry RankSector Rank
Current Ratio 12.15
Quick Ratio 12.15
MTCR Yearly Current Assets VS Current LiabilitesMTCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 69.63% over the past year.
EPS 1Y (TTM)69.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MTCR will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.09% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y70.87%
EPS Next 2Y36.17%
EPS Next 3Y23.37%
EPS Next 5Y12.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTCR Yearly Revenue VS EstimatesMTCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 500K 1M
MTCR Yearly EPS VS EstimatesMTCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MTCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTCR Price Earnings VS Forward Price EarningsMTCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTCR Per share dataMTCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as MTCR's earnings are expected to grow with 23.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.17%
EPS Next 3Y23.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MTCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METACRINE INC

NASDAQ:MTCR (2/8/2023, 8:00:01 PM)

After market: 0.4701 -0.02 (-5.01%)

0.4949

0 (-0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)03-28 2023-03-28/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners20.97%
Ins Owner Change0%
Market Cap21.07M
Analysts45.71
Price Target0.51 (3.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.9%
Min EPS beat(2)-21.38%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)23.22%
Min EPS beat(4)-21.38%
Max EPS beat(4)50.05%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-75%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.15
Quick Ratio 12.15
Altman-Z -5.64
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)34.15%
Cap/Depr(5y)122.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.16%
EPS Next Y70.87%
EPS Next 2Y36.17%
EPS Next 3Y23.37%
EPS Next 5Y12.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.24%
OCF growth 3YN/A
OCF growth 5YN/A